Saturday, September 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Latham Group Shares Draw Conflicting Signals From Major Players

Dieter Jaworski by Dieter Jaworski
September 6, 2025
in Analysis, Earnings, Insider Trading
0
Latham Stock
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

The investment landscape for Latham Group, Inc. presents a complex picture as significant institutional buying activity clashes with a persistent bearish stance from a major investment bank. This divergence of opinion is creating a notable dilemma for market participants evaluating the swimming pool manufacturer’s prospects.

Robust Quarterly Performance

Latham Group’s operational fundamentals demonstrated strength in its second quarter 2025 financial results. The company reported a 7.8 percent increase in revenue alongside a 15.7 percent rise in adjusted EBITDA. Chief Executive Officer Scott M. Rajeski attributed this positive performance to the company’s diversified product portfolio, strong market position, and successful acquisition strategy. Management subsequently reaffirmed its full-year 2025 guidance.

Institutional Investors Expand Positions

Contrasting with the cautious analyst view, institutional investors have been actively accumulating positions in Latham. AYAL Capital Advisors Ltd. established a new holding during the first quarter of 2025, acquiring 567,900 shares valued at $3.65 million. This investment represents 0.49 percent of the company’s outstanding shares and ranks as the 26th largest position in AYAL’s portfolio. They are not alone in their interest; other prominent institutions including BNP Paribas Financial Markets and the New York State Common Retirement Fund have either established new positions or increased their existing stakes in the company.

Should investors sell immediately? Or is it worth buying Latham?

Goldman Sachs Maintains Cautious Stance

Despite this institutional accumulation and strong quarterly results, Goldman Sachs maintains its skeptical outlook. The investment bank recently increased its price target from $4.00 to $4.50 per share but notably preserved its “Sell” recommendation. This position stands in sharp contrast to the broader analyst consensus, which currently rates the stock as a “Moderate Buy” with an average price target of $7.95.

The conflicting perspectives between bullish institutional investors and Goldman Sachs’s continued skepticism have created uncertainty in the market. Investors now face the decision of whether to align with the long-term confidence demonstrated by major funds or heed the investment bank’s more cautious short-term assessment.

Ad

Latham Stock: Buy or Sell?! New Latham Analysis from September 6 delivers the answer:

The latest Latham figures speak for themselves: Urgent action needed for Latham investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 6.

Latham: Buy or sell? Read more here...

Tags: Latham
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

EverQuote Stock
Analysis

EverQuote Stock: Strong Fundamentals Clash With Bearish Market Signals

September 6, 2025
Assembly Biosciences Stock
Analysis

Assembly Biosciences Shares Continue Downward Trajectory

September 6, 2025
Protara Therapeutics Stock
Analysis

Protara Therapeutics: A Study in Contrasts Amid Financial Backing and Market Pressure

September 6, 2025
Next Post
Franklin Stock

Franklin Resources Grapples With Persistent Outflows Despite Record AUM

Potbelly Stock

Sandwich Chain Potbelly Fuels Expansion Ambitions Through Franchise Push

Outfront Media Stock

Outfront Media Dividend Approaches Amid Mixed Financial Signals

Recommended

Altimmune Stock

Altimmune Faces Investor Lawsuit Amid Mixed Clinical Trial Results

3 weeks ago
Healthcare Services Stock Exchange

UnitedHealth Group Reports Impressive Financial Results for Fiscal Year 2023 and Sets Optimistic Goals for 2024

2 years ago
Insurance company Stock Market Today

Legal Action Initiated by James River Group Holdings to Enforce Stock Purchase Agreement against Fleming Intermediate Holdings

1 year ago
Alphabet Stock

Strategic Cloud Alliance with Meta Fuels Alphabet’s AI Ambitions

4 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet AMD AMZN Apple ASML BA Broadcom C Coinbase COST CRWD DIS Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSFT NIO Nvidia Opendoor Oracle PayPal Pepsi PLTR Realty Income Red Cat Rocket Lab USA SMCI Strategy Tesla Tilray TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Urban Outfitters Stock Soars on Exceptional Quarterly Performance

Odyssey Marine Stock: Navigating Volatility with Strategic Progress

Insider Sales at Lemonade Reflect Tax Strategy, Not Pessimism

Pernod Ricard Shares Show Muted Response to Chinese Tariff Relief

Perspective Therapeutics Charts New Course with CFO Appointment Amid Technical Concerns

Indianapolis Emerges as Animal Health Innovation Hub Through Elanco’s Strategic Move

Trending

EverQuote Stock
Analysis

EverQuote Stock: Strong Fundamentals Clash With Bearish Market Signals

by Dieter Jaworski
September 6, 2025
0

EverQuote finds itself at a curious crossroads, presenting investors with a complex puzzle. The online insurance marketplace...

Assembly Biosciences Stock

Assembly Biosciences Shares Continue Downward Trajectory

September 6, 2025
Protara Therapeutics Stock

Protara Therapeutics: A Study in Contrasts Amid Financial Backing and Market Pressure

September 6, 2025
Urban Outfitters Stock

Urban Outfitters Stock Soars on Exceptional Quarterly Performance

September 6, 2025
Odyssey Marine Exploration Stock

Odyssey Marine Stock: Navigating Volatility with Strategic Progress

September 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • EverQuote Stock: Strong Fundamentals Clash With Bearish Market Signals September 6, 2025
  • Assembly Biosciences Shares Continue Downward Trajectory September 6, 2025
  • Protara Therapeutics: A Study in Contrasts Amid Financial Backing and Market Pressure September 6, 2025

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com